Article

Neoadjuvant combo efficacious in high-risk prostate cancer

One-third of men with high-risk prostate cancer achieved pathologic complete response (pCR) or near-complete response to 6 months of preoperative therapy with abiraterone acetate (ZYTIGA), leuprolide, and prednisone, investigators reported at the American Society of Clinical Oncology annual meeting in Chicago.

Related Videos
Sarah Razavi, MD, answers a question during a Zoom video interview
1 expert in this video
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
1 expert in this video
1 expert is featured in this series.
1 expert in this video
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
4 experts in this video
Related Content
© 2025 MJH Life Sciences

All rights reserved.